Harrow (HROW) Stock: Buy, Sell, or Hold?
HROW - Harrow, Inc. Common Stock
$28.15
-0.09 (-0.32%)
▼
5d:
-2.09%
30d:
-16.22%
90d:
-26.79%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 09, 2026
17d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 20, 2026 at $28.52 · last confirmed Oct 20, 2026
Strength: 6.7/10
Get Alerted When HROW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HROW shows positive signals but monitor for confirmation. Market pricing in 15.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: HROW shows positive signals but monitor for confirmation. Market pricing in 15.4% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$90.70
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$56.32
50.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HROW is currently trading at $28.15, which is considered oversold relative to its 30-day fair value range of $28.56 to $33.20. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.2) compared to its historical average (16.8). Remarkably, the market is currently pricing in an annual earnings decline of 15.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HROW is in a strong downtrend. Immediate support is located at $26.96, while resistance sits at $30.90.
Market Sentiment: HROW scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $65.00 (+130.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HROW is in a strong downtrend. Immediate support is located at $26.96, while resistance sits at $30.90.
Market Sentiment: HROW scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $65.00 (+130.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$28.56 -
$33.20
Company Quality Score
59/100
(HOLD)
Options IV Signal
30th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 30th percentile)
- BULLISH: Strong technical setup (67/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 130.2% below Wall St target ($65.00)
- BULLISH: Bottoming setup score 67/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$28.56 -
$33.20
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.57
(12.7%)
Support & Resistance Levels
Support Level
$26.96
Resistance Level
$30.90
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.19
Wall Street Target
$65.00
(+130.2%)
Revenue Growth (YoY)
10.9%
Earnings Growth (YoY)
-10.3%
Profit Margin
-13.5%
Valuation Discount vs History
-15.4% cheaper
PE vs Historical
10.2 vs 16.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-15.4%
(market-implied from PE analysis)
1-Year Target
$25.42
(-10%)
2-Year Target
$22.87
(-19%)
3-Year Target
$20.59
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→17)
$33.96
(+20%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 539.9%)
$185.83
(+558%)
Base:
(SPY PE: 10.2, Growth: 539.9%)
$95.31
(+238%)
Bear:
(PE: 8.7, Growth: 539.9%)
$81.01
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.2 to 16.8
Stabilization Target:
$46.58
(+64.9%)
PE Expansion Potential:
+64.9%
Share & Embed Analysis
Last updated: October 22, 2026 4:18 PM ET
Data refreshes hourly during market hours. Next update: 5:18 PM
Data refreshes hourly during market hours. Next update: 5:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HROW showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 51 HOLD |
Advanced HROW Option Strategies
Professional options setups generated by AI based on today's HROW price and gamma walls.
